[LAST CALL] 12 more days to apply for the #CVCT Future Trialists Fellowship ! Time to create your future: www.globalcvctforum.com/future-trial...
Find out more here: www.globalcvctforum.com/fellowships
#clinicaltrials #clinicalresearch #fellowship #CVCT2026
#CVCT2025: NEW! December 8-10, visit the patient trialists lounge at #CVCT!
- Talk one on one with patient trialists
- Ask specific questions about your trial
- Brainstorm solutions to your challenges
Register and join us: www.globalcvctforum.com
[CALL FOR APPLICATION] There is increasing need to bolster clinical trilas experience for CV fellows and junior faculty, and only limited options to pursue rigorous training and solid experience in CT. Apply for the #CVCT Future Trialists Fellowship: www.globalcvctforum.com/future-trial...
03.12.2025 16:13 — 👍 1 🔁 1 💬 0 📌 0
Join the discussion, December 8-10, Washington DC: www.globalcvctforum.com/scientific-p...
21.11.2025 18:18 — 👍 0 🔁 0 💬 0 📌 0
Discussions on the utility of beta-blockers in post-MI patients 'been ongoing for the last 50 years. Early trials documented survival benefits for MI patients, but the entire therapeutic landscape has undergone fundamental changes based on revascularization strategies and post-infarction prevention.
21.11.2025 18:18 — 👍 2 🔁 1 💬 1 📌 0
Join us for ample discussion on how to bridge the gap from concept to clinic: www.globalcvctforum.com/scientific-p...
#CKLM #RNAtherapeutics #CardioInnovation #TranslationalMedicine #CVCT
#CVCT2025: “CKLM BIOLOGICS: From Concept to Clinic” — a deep dive into overcoming translational & regulatory barriers for next-gen cardiovascular therapies.
Global leaders will discuss cardiogenic shock, RNA & antibody platforms, AI, biomarkers, bench to bedside success stories and trial innovation.
Dr. John Spertus, MD, MPH, FACC has been selected by the 2025 CVCT Patient Advisory Board as the inaugural recipient for his pioneering innovation and continued excellence in Patient Engagement in Clinical Research. CONGRATULATIONS!
#CVCT #patienttrialists
www.globalcvctforum.com
NEW at #CVCT2025: The Cynthia Chauhan Trailblazer Award, named for CVCT’s founding Patient Trialist, is presented to a researcher who has demonstrated exemplary commitment to patient engagement in clinical research.
30.10.2025 19:28 — 👍 0 🔁 0 💬 1 📌 0
Join us for what promises to be a fascinating insight into the leading-edge clinical science and the thinking driving progress in the field of hypertension. www.globalcvctforum.com/scientific-p...
Professor Bryan Williams OBE
With new therapeutic targets as aldosterone synthase, angiotensinogen, natriuretic peptides, as well as novel modes of therapeutic delivery such as RNA silencing and peptide modification to extend duration of action, the potential of these new treatments and their place in the hierarchy of therapy
24.10.2025 15:14 — 👍 0 🔁 0 💬 1 📌 0
#CVCT2025: The Think Tank we have assembled around EVOLUTION OF NEW THERAPIES FOR HYPERTENSION - WHAT IS THEIR PLACE IN MODERN TREATMENT STRATEGIES? will discuss the extraordinary renaissance of new therapies for the treatment of hypertension at various stages in drug development.
24.10.2025 15:14 — 👍 0 🔁 0 💬 1 📌 0
#CVCT2025: Browse our scientific program and join us, December 8-10, Washington DC!
www.globalcvctforum.com/scientific-p...
#CVCT #clinicaltrials #clinicalresearch
Sessions will highlight practical IND strategies and frameworks for safety monitoring developed by leading teams. Experts will also discuss emerging models for ensuring safety, access, and reimbursement.
Join us, December 8-10, Washington DC! www.globalcvctforum.com/scientific-p...
#CVCT2025: How can gene therapy be effectively implemented in rare and complex cardiovascular conditions? This section addresses patient selection, the design of adaptive clinical trials, and regulatory pathways tailored for orphan populations.
14.10.2025 16:49 — 👍 0 🔁 0 💬 1 📌 0Don’t miss your chance to share your work and be part of the global discussion shaping the future of cardiovascular clinical research!
10.10.2025 13:17 — 👍 0 🔁 0 💬 0 📌 0
For simultaneous full manuscript publication in JACC, please contact directly cvct-abstracts@overcome.fr for additional information.
For any additional questions, please contact us at cvct-abstracts@overcome.fr
2. Late-Breaking Clinical Trials (LBCTs)
Submissions for Late-Breaking Clinical Trials are also open until October 20, 2025.
👉Find the guidelines and the submission link here: www.globalcvctforum.com/late-breakin...
We’re excited to share an important update:
1. Abstract Submissions – New Deadline: October 20, 2025
We are now accepting abstracts from both industry and academic contributors.
👉Find the guidelines and the submission link here: : www.globalcvctforum.com/poster-prese...
This session will include highly anticipated debates on the role and feasibility of placebo-controlled device trials as well as on the optimal approach to analysis and reporting of health status and quality of life endpoints.
Join us, Dec 8-10, Washington DC: www.globalcvctforum.com/scientific-p...
#iCVCT2025: At iCVCT, there will be a unique menu of sessions covering clinical trial design and regulatory considerations for cardiovascular devices. I am particularly excited about the session on Controversies in Clinical Trial Design for Structural Heart Interventions.
03.10.2025 17:06 — 👍 0 🔁 0 💬 1 📌 0
- All accepted abstracts will be published in the Journal of American College of Cardiology.
- Full manuscripts will be eligible for simultaneous publication with fast-track review by JACC.
Submission Deadline - October 15
Find out more here: www.globalcvctforum.com/late-breakin...
CVCT meeting attract global leaders representing all aspects of clinical trials including trialists, clinicians, sponsors, regulators, funders, payers, editors, and patients and advocacy groups. Your research results will find a broad expert audience.
01.10.2025 07:22 — 👍 0 🔁 0 💬 1 📌 0
#CVCT2025: This year, you have the opportunity to share impactful, cutting-edge results on a global stage and to contribute to shaping the future of innovative therapies and clinical trial science.
01.10.2025 07:22 — 👍 0 🔁 0 💬 1 📌 0
and attempts to trigger a true myocardial regeneration by a mRNA-based activation of endogenous pathways involved in cardiomyocyte cycling and division.
Discover our scientific program and join us, December 8-10, 2025, Washingto, DC: www.globalcvctforum.com/scientific-p...
reassessment of delivery routes and dosing strategies taking into account the role of the immune landscape as a key driver of heart failure and aimed at streamlining the implementation of both cell-based and secretome-based strategies;
25.09.2025 21:17 — 👍 0 🔁 0 💬 1 📌 0
transplantation of cardiomyocytes differentiated from pluripotent stem cells to induce remuscularization of the chronically failing heart; switch towards the exclusive use of the cellular secretome shown to duplicate the cardio-protective effects of the parental cells;
25.09.2025 21:17 — 👍 0 🔁 0 💬 1 📌 0
#CVCT2025: Even though outcomes of the early cell therapy trials have not matched the expectations, the concept of leveraging the bioactivity of cells for improving cardiac function in heart failure is still under active development and research now spans the main following areas:
25.09.2025 21:17 — 👍 0 🔁 0 💬 1 📌 0
Discover the program and join us, December 8-10, Washington DC : www.globalcvctforum.com/scientific-p...
#CVCT #CV #clinicalresearch
Those countermeasures and their impact on clinical strategies, timelines, and availability of key medical devices will be discussed during this session. Both the EU and the US will be compared by looking to the pros and cons of both regions with regard to regulatory approval processes.
19.09.2025 16:44 — 👍 0 🔁 0 💬 1 📌 0